RUNX1T1/ETO Antibody - BSA Free

Western Blot: RUNX1T1/ETO Antibody [NBP2-55747]

Western Blot: RUNX1T1/ETO Antibody [NBP2-55747] - H2135 and H2087 non-small cell lung cancer cells showing baseline Runx1T1 expression versus Runx1T1 stable overexpression. Image submitted by a verified customer review.

Immunocytochemistry/ Immunofluorescence: RUNX1T1/ETO Antibody [NBP2-55747]

Immunocytochemistry/Immunofluorescence: RUNX1T1/ETO Antibody [NBP2-55747] - Staining of human cell line HEK 293 shows localization to nucleoplasm. Antibody staining is shown in green.

Western Blot: RUNX1T1/ETO Antibody - BSA Free [NBP2-55747] -

RUNX1T1 is highly expressed in SCLC. (A) RUNX1T1 mRNA levels in cancer cell lines based on Affymetrix data from the CCLE. SCLC is highlighted with a red arrow and NSCLC with a blue arrow. (B) Western blot of RUNX1T1 expression in eight SCLC cell lines (DMS79, H2171, H1694, SHP77, H82, H446, H69, and SW1271) and four NSCLC cell lines (A549, H1299, H1650, and PC9); beta‐actin was used as the loading control. (C) RUNX1T1 mRNA levels in tumor samples detected by RNA‐Seq comparing SCLC with other cancers (BRCA: breast cancer, CR: colorectal cancer, GBM: glioblastoma, LUAD: lung adenoma NSCLC, LUSC: lung squamous NSCLC, PRAD: prostate adenoma cancer, SKCM: skin melanoma cancer). (D) RUNX1T1 in situ hybridization examples using RNAscope on clinical tumor samples of ‘pure’ SCLC, lung adenocarcinoma and lung squamous cell carcinoma. Red dots identify RUNX1T1 mRNA signal, green dots MYC mRNA signal. Scale bar = 50 um. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33084222), licensed under a CC-BY license. Not internally tested by Novus Biologicals.